VistaGen gets Nasdaq extension to regain $1 minimum bid price compliance - VTGN News | RalliesVistaGen gets Nasdaq extension to regain $1 minimum bid price compliance
V
VTGN• Nasdaq grants 180-day cure period
- VistaGen Therapeutics won a 180-day Nasdaq extension to regain compliance with the $1 minimum bid price rule.
- The new deadline is Feb. 1, 2027; the shares remain listed on the Nasdaq Capital Market during the cure period.
- Failure to regain compliance by the deadline would trigger a delisting notice; the company could appeal to a Nasdaq hearings panel.
CAPL
•
